Synthomer Issues New Equity to Lenders as Analyst Optimism Grows on Margin Tailwinds

Synthomer issues 430,008 shares to creditors for refinancing fees, gains from butadiene supply constraints, but faces Moody's downgrade and balance sheet risks.

The specialty chemicals group Synthomer is pressing ahead with its balance sheet repair, issuing 430,008 new ordinary shares to creditors as payment for fees tied to its ongoing refinancing effort. The stock, equivalent to roughly 0.26% of existing share capital, is slated to begin trading on the London Stock Exchange on 8 May 2026, with admission already applied for.

The move comes at a time of contrasting narratives around the company. On one hand, a tightening supply of the key raw material butadiene — stemming from reduced flows out of Asia and Iran — is providing a welcome margin boost. Berenberg analysts have lifted their price target sharply to 100 pence from 60 pence, citing the temporary supply constraints as a catalyst for improved profitability. The bank has raised its 2026 EBITDA forecast by £60 million, with more moderate upward revisions of £30 million for 2027 and £11 million for 2028. Despite the upgraded target, Berenberg maintains a "Hold" rating on the stock.

That caution reflects the other side of the story: lingering balance sheet strain. While management successfully renegotiated credit terms in late April, averting a debt exchange, Moody’s delivered a mixed verdict. The rating agency affirmed Synthomer’s Caa1 corporate family rating but downgraded its bond rating to Caa2, slapping a "Limited Default" tag on the issuer default rating. The designation underscores the risks embedded in the capital structure even as operational conditions improve.

The equity issuance — representing a modest dilution for existing holders — is a deliberate step to prioritise debt reduction. Synthomer has framed the move as a necessary phase of intensive balance sheet management following a volatile market period. The company’s focus on stabilising its capital structure is taking precedence over near-term shareholder returns.

Meanwhile, insider activity has offered a vote of confidence. Lily Liu acquired roughly 29,200 shares at 66 pence in late April. The stock now trades around 86.80 pence, nearly in line with the consensus analyst estimate. The shares have climbed 37% since the start of the year, reflecting growing optimism that the worst of the financial turbulence may be behind the company.

Analysts currently rate the stock a "Hold" with a price target of 65.00 British pounds, though the Berenberg revision suggests a more bullish camp is emerging. The industrial backdrop for Synthomer’s polymer solutions in construction and healthcare is also showing signs of stabilisation, adding to the cautiously optimistic outlook.

Whether the butadiene-driven margin tailwinds prove durable will be key to sustaining the earnings momentum that underpins the latest analyst upgrades. For now, Synthomer is navigating a delicate balancing act between operational opportunity and financial repair.